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Human herpes simplex virus 1 (HSV-1) encephalitis can be caused by inborn errors of the TLR3 pathway, resulting in
impairment of CNS cell-intrinsic antiviral immunity. Deficiencies of the TLR3 pathway impair cell-intrinsic immunity to
vesicular stomatitis virus (VSV) and HSV-1 in fibroblasts, and to HSV-1 in cortical but not trigeminal neurons. The underlying
molecular mechanism is thought to involve impaired IFN-α/β induction by the TLR3 recognition of dsRNA viral intermediates
or by-products. However, we show here that human TLR3 controls constitutive levels of IFNB mRNA and secreted bioactive
IFN-β protein, and thereby also controls constitutive mRNA levels for IFN-stimulated genes (ISGs) in fibroblasts. Tlr3–/–
mouse embryonic fibroblasts also have lower basal ISG levels. Moreover, human TLR3 controls basal levels of IFN-β secretion
and ISG mRNA in induced pluripotent stem cell–derived cortical neurons. Consistently, TLR3-deficient human fibroblasts and
cortical neurons are vulnerable not only to both VSV and HSV-1, but also to several other families of viruses. The mechanism
by which TLR3 restricts viral growth in human fibroblasts and cortical neurons in vitro and, by inference, by which the human
CNS prevents infection by HSV-1 in vivo, is therefore based on the control of early viral infection by basal IFN-β immunity.

Introduction

TLR3 on endosomes recognizes double-stranded RNA (dsRNA)
intermediates or by-products generated during viral infection.
TLR3 signaling leads to the activation of IFN regulatory factor 3
(IRF3), NF-κB, and ATF/c-jun, promoting the induction of antiviral IFNs and downstream IFN-stimulated genes (ISGs) (1–4). The
discovery of inborn errors of human TLR3 and its pathway in chil-
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dren with herpes simplex virus 1 (HSV-1) encephalitis (HSE) led
to the suggestion that TLR3 serves as a key sensor for HSV-1 replication in the CNS (5–7). Childhood HSE is a rare, sporadic, and
life-threatening complication of primary infection with HSV-1 in
which the virus replicates in the CNS. HSV-1 infection is ubiquitous in the general population. The virus resides in the trigeminal
(TG) ganglion, where it remains latent, but can later reactivate to
cause benign herpes labialis or other rare complications, including HSE (8). The pathogenesis of HSE remained unexplained until
our description of the first genetic etiologies for this disease (9,
10). Germline HSE-causing mutations have since been reported
in 7 genes of the TLR3 pathway (TLR3, UNC93B1, TRIF, TRAF3,
TBK1, IRF3, NEMO) and 2 genes of the IFN-α/β receptor pathway (IFNAR1, STAT1) (9–17). UNC-93B is a membrane-bound
molecule that regulates the signaling of endosomal TLR3, TLR7,
TLR8, and TLR9 by binding to their transmembrane domains and
1
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maintaining TLR3 expression (18–21). TRIF is the sole adaptor
of TLR3, whereas TRAF3, TBK1, IRF3, and NEMO are key molecules required for the TLR3-TRIF–dependent induction of antiviral IFNs (7). Candidate mutations in other genes of the pathway
have also been reported (22). Mutations of TLR3 pathway genes
have been shown to impair the TLR3-dependent induction of antiviral IFNs, whereas IFNAR1 and STAT1 mutations impair cellular
responses to type I IFNs. Collectively, these findings suggest that
HSE can result from the impaired production of IFN-α/β and/or
IFN-λ in response to TLR3 stimulation by HSV-1 in the CNS.
This hypothesis was initially supported by experiments conducted in dermal fibroblasts infected with HSV-1 and another
neurotropic virus, vesicular stomatitis virus (VSV), an ssRNA virus
typically innocuous in humans, chosen for these studies because it
is highly cytopathic and induces IFN more effectively than HSV-1
in these cells (23). Fibroblasts with TLR3 signaling deficiencies
display impaired responses to the TLR3 agonist polyinosinicpolycytidylic acid (poly(I:C)), a synthetic analog that mimics dsRNA by-products and intermediates of viral replication. Following
infection with HSV-1 or VSV, TLR3 pathway–deficient fibroblasts
produce less IFN-β and -λ than control cells, and display higher
rates of viral replication and virus-induced cell death (9–11, 13–16,
24). Moreover, the viral phenotype of fibroblasts from patients
with mutations of TLR3 pathway genes is rescued by pretreatment with IFN-α or -β, but not IFN-λ (9–11, 13–16, 24). The viral
phenotype of fibroblasts from patients not responding to IFN-α/β
and -λ due to STAT1 deficiency is not rescued by any type of IFN
(10). We have also shown that cortical neurons and oligodendrocytes derived from TLR3-deficient induced pluripotent stem cells
(iPSCs) display impaired IFN responses to poly(I:C) and HSV-1,
and do not control HSV-1, with this viral phenotype being rescued
by pretreatment with IFN-α or -β but not IFN-λ (25). Collectively,
these findings suggest that the viral (HSV-1 and VSV) and IFN-β
phenotypes of TLR3-deficient fibroblasts observed in vitro are a
surrogate for that of iPSC-derived cortical neurons in vitro and
predisposition to HSE in vivo.
Unlike iPSC-derived cortical neurons, iPSC-derived peripheral TG neurons from healthy donors control HSV-1 as poorly as
poly(I:C)-unresponsive TLR3-deficient TG neurons, in terms of
viral growth (26). Pretreatment with IFN-α or -β, but not IFN-λ,
rescues susceptibility to viral infections in both types of TG neurons, whereas pretreatment with poly(I:C) rescues only control
TG neurons, in which IFNs and ISGs are induced in response to
TLR3-dependent poly(I:C) stimulation. These data indicate that
TG neurons are vulnerable to HSV-1 in the absence of preemptive stimulation via TLR3 or IFN-α/β receptors, whereas control
cortical neurons display TLR3-dependent constitutive resistance
that is sufficiently strong to block incoming HSV-1 in the absence
of prior antiviral signals. This experimental observation in vitro
is consistent with HSV-1 infecting TG neurons and establishing
latency in these cells, but not in cortical neurons in vivo in most
individuals (27). Overall, these findings suggest a cellular model
of HSE with a TLR3-dependent IFN-mediated phenotype in fibroblasts and iPSC-derived cortical but not TG neurons. However,
the molecular basis of these 2 cellular phenotypes in vitro and of
HSE in vivo remained unexplained. Indeed, although both HSV-1
and VSV produce dsRNAs (28, 29), HSV-1 recognition depends
2

largely on the cGAS DNA sensor in mouse fibroblasts and myeloid
cells (30), whereas VSV recognition in mouse fibroblasts is dependent on RIG-I (31). It therefore remained unclear whether TLR3
actually recognizes dsRNA intermediates or by-products generated during the infection of fibroblasts and cortical neurons with
HSV-1 and VSV, or whether it controls the IFN-mediated immunity
of these cells against these viruses by other mechanisms. As a
first step toward addressing this question, we performed a comprehensive analysis of the connection between IFN induction and
VSV infection in human fibroblasts. We then investigated whether
our findings also applied to HSV-1 infection in iPSC-derived
cortical and TG neurons.

Results

RIG-I–dependent overproduction of IFN-β and -λ in response to VSVM51R in TLR3-deficient fibroblasts. In human fibroblasts, high levels of mRNA for IFN-β and IFN-λ (including all 3 types of IFN-λ,
IFNL1, IFNL2, and IFNL3), but not other subtypes of antiviral IFNs,
can be induced by extracellular poly(I:C) stimulation, which activates TLR3 in endosomes (Supplemental Figure 1; supplemental
material available online with this article; https://doi.org/10.1172/
JCI134529DS1), or intracellular poly(I:C) stimulation, which activates RIG-I and MAD5 in the cytosol (Supplemental Figure 1) (28).
We hypothesized that, if the higher levels of viral growth and cell
death observed in TLR3-deficient cells were due to an impairment
of virus-induced IFN production, then a potent IFN-inducing
stimulus would rescue viral susceptibility. We made use of a natural mutant of VSV, VSV-M51R, which induces IFN very strongly in
most of the cells tested, much more so than VSV-WT (32, 33). We
first assessed the production of IFN-β and -λ following infection
with VSV-WT and -M51R at various MOIs for 24 hours, in simian virus 40 (SV-40) T antigen–transformed fibroblasts (SV-40
fibroblasts) from a healthy control, a patient with HSE with autosomal recessive (AR) UNC-93B deficiency (UNC-93B–/–), and a
patient with HSE with AR TLR3 deficiency (TLR3–/–). Surprisingly,
UNC-93B–/– and TLR3–/– cells produced about 30 times more
IFN-β than healthy control cells after 24 hours of infection with
VSV-M51R at a MOI of 0.01 (Figure 1A). Similar results were
obtained for IFN-λ (as measured by ELISA, which recognizes all
IFN-λ1/2/3 in a nonspecific manner, Supplemental Figure 2, A
and B). NEMO–/– fibroblasts displayed no activation of the transcription factors IRF3 and NF-κB in response to viral infection
(11, 32), and were thus included as a negative control (Figure 1A).
Consistently, IFNB and IFNL1 mRNA levels were higher in UNC93B–/– and TLR3 –/– cells than in healthy control cells 24 hours after
infection with VSV-M51R or -WT (Figure 1B, Supplemental Figure
2C), although no IFN-β or IFN-λ was detected by ELISA in UNC93B–/– and TLR3–/– cells following VSV-WT infection (Figure 1A,
Supplemental Figure 2A). In UNC-93B–/– and TLR3–/– fibroblasts,
the response to TLR3 stimulation with extracellularly added
poly(I:C) was completely abolished, whereas the responses to
transfection with poly(I:C) (a nonspecific agonist of RIG-I and
MDA5) and 7sk-as (a specific agonist of RIG-I) were intact (Figure
1A, Supplemental Figure 3, A–C) (9, 10). IFN induction in response
to VSV may be RIG-I dependent, as suggested by previous studies on mouse embryonic fibroblasts (MEFs) (28, 31, 33). Indeed,
following the short-hairpin RNA–mediated (shRNA-
mediated)
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Figure 1. Paradoxical IFN response
to VSV-M51R infection in fibroblasts
with TLR3 signaling deficiencies.
(A) IFN-β production in SV-40–transformed dermal fibroblasts (SV-40
fibroblasts) left nonstimulated (NS),
treated with poly(I:C), or infected with
VSV-WT (WT) or VSV-M51R mutant
at various MOIs (0.01, 0.1, 1) for 24
hours, as measured by ELISA. C1 is a
healthy control. (B) IFN-β mRNA
levels in fibroblasts left NS or
infected for 24 hours with VSV-WT
or -M51R at a MOI of 1. β-glucuronidase mRNA levels were used for
normalization. The error bars indicate
SD of biological triplicates from 3
independent experiments. P values
were obtained for 1-way ANOVA and
subsequent Tukey’s multiple comparison tests. (C) dsRNA from VSV-WT–
and VSV-M51R–infected fibroblasts,
visualized by electrophoresis in
1.5% agar gels, blotting onto nylon
membranes and incubation with a
monoclonal antibody against dsRNA.
Ethidium bromide (EtBr) staining of
the agar gel is shown as a loading
control. Data from 3 independent
experiments are shown. **P < 0.01,
***P < 0.001, ****P < 0.0001.

knockdown of RIG-I or its downstream signaling molecule MAVS
(34–37), the production of IFN-β in response to VSV-M51R infection, or to transfected poly(I:C) and 7sk-as, was much weaker
in RIG-I or MAVS-knockdown UNC-93B–/– cells than in those
transduced with a control scrambled RNA, indicating the essential role of RIG-I in sensing VSV-M51R (Supplemental Figure 3, A
and B). Thus, VSV-M51R can induce IFN-β or IFN-λ via RIG-I in
UNC-93B–/– and TLR3 –/– fibroblasts, and, paradoxically, UNC93B–/– and TLR3 –/– cells respond to VSV-M51R by producing markedly larger amounts of IFN-β and -λ than control cells.
The hyper-IFN response to VSV-M51R in TLR3-deficient fibroblasts is triggered by enhanced viral replication. We then investigated
whether RIG-I was hyperactive in UNC-93B–/– fibroblasts, which
would account for IFN overinduction as a means of compensating
for the lack of TLR3 signaling. We overcame the problem of the
confounding effect of a larger viral stimulus in UNC-93B–/– cells
by transfecting the fibroblasts with total cellular RNA isolated
from VSV-WT– or VSV-M51R–infected Vero cells (vRNA). IFN-β
production levels were almost identical between UNC-93B–/– and
healthy control cells stimulated by transfection with vRNA (Supplemental Figure 3C). As no viral proteins antagonistic to IFN
were produced, VSV-WT and VSV-M51R RNA induced IFN-β to
similar levels (Supplemental Figure 3C). This result suggests that
the RIG-I pathway is equally active in the cells of patients with
UNC-93B deficiency and healthy controls. Moreover, when we

coinfected fibroblasts with both VSV-WT and VSV-M51R, the high
levels of IFN-β production induced by the M51R virus were completely abolished by coinfection with VSV-WT (Supplemental Figure 3D) (38). This suggests that the inability to block mRNA export
from the nucleus, and thus, to abolish IFN production by VSV-WT,
is responsible for this phenomenon rather than the stimulation,
by VSV-M51R, of an additional signaling pathway different from
that stimulated by the WT virus (39). However, consistent with
the high levels of virus-triggered IFN-β and IFN-λ production in
UNC-93B–/– and TLR3–/– fibroblasts, we detected substantially
more dsRNA in the cells of patients with UNC-93B and NEMO
deficiency than in control fibroblasts (Figure 1C), 8 hours after
VSV-WT or -M51R infection, by Western blotting with anti–
dsRNA antibody (28). The high levels of dsRNA are also consistent with the previously known rapid VSV-WT replication in
UNC-93B–/– and TLR3 –/– fibroblasts (9, 10, 13), which was confirmed by determining VSV glycoprotein (VSV-G) mRNA levels
by quantitative real-time PCR (RT-qPCR) (Supplemental Figure
3E). Interestingly, the induction of IFNB mRNA by VSV-WT was
detectable only at late time points (not at the 6 hour time point)
(Supplemental Figure 3F), suggesting that viral replication is
required for IFN induction. Indeed, this enhanced production
of IFN in UNC-93B–/– and TLR3 –/– cells required an actively replicating virus, as the ultraviolet irradiation of VSV-WT and -M51R
blocked their stimulatory effect (Supplemental Figure 3G). Thus,
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kinetics and virus-induced cell death.
Surprisingly, although VSV-M51R complemented the IFN phenotype, with IFN
levels even exceeding those observed in
controls, this potent induction of IFN production by the virus did not decrease viral
replication and cell mortality in TLR3–/– or
UNC-93B–/– SV-40 fibroblasts upon infection with VSV-M51R at a MOI of 1, from
0.5 hour to 24 hours after infection. Both
the WT and M51R viruses replicated much
more rapidly in UNC-93B–/– and TLR3 –/–
cells than in control cells, and, by 6 hours
after infection, there was at least a 100fold difference in titer (Figure 2, A and
B), whereas IFN induction was not readily
detectable at this time point (Supplemental Figure 3F). We then measured VSV
replication, by assessing viral VSV-G RNA
levels in fibroblasts from patients with
inborn errors of TLR3 (TLR3, UNC93B1,
NEMO) or IFN (STAT1, STAT2) immunity
(40, 41), comparing these levels with
those in WT control cells. VSV levels were
markedly higher in the cells of all patients
16 hours after infection (Figure 2, C and
D; and Supplemental Figure 4, A and B).
Moreover, cell death rates were greater in
UNC-93B–/– cells than in control cells after
24 hours of VSV-WT or -M51R infection
(Figure 2, E and F), despite the extremely
high levels of IFN production following
infection with VSV-M51R (Figure 1, A and
B; Supplemental Figure 2, A–C). Thus,
although the production of larger amounts
Figure 2. Unrestricted virus growth and cytotoxicity in fibroblasts with TLR3 signaling deficiencies.
of immunostimulatory viral replication
VSV-WT (A) and VSV-M51R (B) single-cycle replication curves for fibroblasts from healthy controls (C1 and
intermediates in TLR3 pathway-deficient
C2) and patients with UNC-93B or TLR3 deficiency at a MOI of 1 over 24 hours. Control fibroblasts (C1–C4)
fibroblasts, such as dsRNA (Figure 1C),
and TLR3–/–, UNC93B–/–, NEMO–/–, STAT1–/–, and STAT2–/– fibroblasts were infected with VSV-WT (C) and
led to enhanced IFN production by the
VSV-M51R (D) at a MOI of 0.01 for 16 hours. Viral VSV-G RNA levels were then determined by RT-qPCR and
patients’ cells upon infection with VSVnormalized against C1. Cell mortality following infection with VSV-WT (E) and VSV-M51R (F) at a MOI of 1
for C1, UNC-93B–/–, and NEMO–/– fibroblasts, as measured by the release of lactate dehydrogenase (LDH)
M51R, this enhanced IFN production was
at the times indicated, in hours postinfection (hpi). Values are expressed relative to those for uninfected
not sufficient to protect these cells against
cells. Triplicate measurements from 3 independent experiments (A–B, E–F) or representative results from
viral replication, which reached very high
3 independent experiments (C–D) are shown. The error bars indicate SD of biological triplicates. P values
levels before IFN production was induced
were obtained through log transformation followed by 1-way ANOVA and subsequent Tukey’s multiple
by the virus.
comparison tests (A–B) or likelihood ratio tests (C–D), by comparing each patient’s fibroblasts with control fibroblasts, and the respective P value is indicated. *P < 0.05, **P < 0.01, ***P < 0.001.
General antiviral defect in fibroblasts
with deficiencies of the TLR3 and IFN signaling pathways. We then assessed the
susceptibility of UNC-93B–/– and TLR3–/– fibroblasts to other virusthe potent IFN production observed after VSV-M51R infection in
cells with TLR3 pathway deficiencies was due to the presence of
es, which may or may not rely on TLR3 for virus-triggered IFN
large amounts of dsRNA upon infection, rather than hyperactive
induction, by evaluating viral replication and virus-induced cell
RIG-I signaling.
death. We found that another ssRNA virus, human parainfluenza
Uncontrolled VSV-M51R replication and virus-induced cell death
virus 3 (hPIV3), like VSV, replicated faster and to higher titers in
in TLR3-deficient fibroblasts despite high levels of virus-induced IFN
UNC-93B–/– and TLR3–/– cells than in control cells (Figure 3A).
production. We then investigated the second cellular phenotype
As a result, viral cytotoxicity was also higher in UNC-93B–/– and
related to inborn errors of TLR3 immunity — viral susceptibility —
TLR3–/– fibroblasts (Figure 3B). IFN-β production was similar in
–/–
–/–
in TLR3 and UNC-93B fibroblasts. We measured VSV growth
control and TLR3- or UNC-93B–deficient fibroblasts infected with
4
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IFN pathway–deficient cells than in
control cells (Figure 3E; and Supplemental Figure 4C), 16 hours after
infection, whereas IFNB and IFNL
mRNA induction was detected 24
hours after infection (Supplemental
Figure 4, D and E). Overall, these
data indicate that fibroblasts with
deficiencies of the TLR3 and IFN
signaling pathways are highly susceptible to infection with at least
3 RNA viruses (VSV, hPIV3, and
EMCV) and one DNA virus (HSV-1),
despite a high level of IFN production induced by VSV-M51R and the
normal induction of IFN production by hPIV3 and EMCV in TLR3
pathway–deficient cells. This is paradoxical, as poor IFN production by
these cells upon infection with VSVWT and HSV-1 had been thought to
underlie the cellular vulnerability
to both viruses.
Low basal levels of IFN and
ISG expression in fibroblasts with
TLR3-IFN signaling deficiencies.
Our previous and current data
show that the prior treatment (but
not treatment at the time of infection) of TLR3 signaling–deficient
fibroblasts with recombinant IFNα2b or -β, but not IFN-λ, protects
them against VSV-WT and -M51R,
or HSV-1 replication and virusFigure 3. High susceptibility to different viruses in TLR3 signaling–deficient cells. (A) hPIV3 single-cycle
induced cell death (Supplemental
replication curves in fibroblasts from healthy controls (C1 and C2) and patients with UNC-93B or TLR3 deficiency
Figure 5A) (10). In this study, we
over 24 hours. (B) Viability of fibroblasts 48 hours after infection with hPIV3 at the indicated MOIs. (C) IFN-β
also found that TLR3 signaling–
production, measured by ELISA, after 24 or 48 hours of infection with hPIV3 in C1, C2, UNC-93B–/–, and TLR3–/–
fibroblasts. Control fibroblasts (C1–C4) and TLR3–/–, UNC93B–/–, NEMO–/–, STAT1–/–, and STAT2–/– fibroblasts were
deficient cells sustained very high
infected with EMCV (D) or HSV-1-GFP (E) at a MOI of 0.01 for 16 hours. Viral RNA levels were then quantified by
levels of virus replication before
RT-qPCR, with normalization against the values for C1. Triplicate measurements from 3 independent experithe induction of IFN production
ments (A–C) or representative results from 3 independent experiments (D–E) are shown. The error bars indicate
in response to viral infection (FigSD of biological triplicates. P values were obtained through log transformation followed by 1-way ANOVA and
ure 3E; and Supplemental Figure
subsequent Tukey’s multiple comparison tests (A) or likelihood ratio tests, by comparing each patient’s fibroblasts with control fibroblasts (D, E), and the respective P values are indicated. *P < 0.05, **P < 0.01 ***P < 0.001. 4, C–E). We therefore hypothesized that viral replication might
be limited in control cells by
basal levels of IFNs constitutively expressed in a TLR3-dehPIV3 (Figure 3C), probably reflecting intact IFN induction via
pendent manner. We tested this hypothesis, first by assessing
TLR3-independent pathways. We subsequently challenged fibrobasal levels of IFN production in unstimulated SV-40 fibroblasts with encephalomyocarditis virus (EMCV), another RNA
blasts. Control fibroblasts secreted higher basal levels of IFN-β
virus that has been shown to induce IFN production in an
than TLR3 –/– or UNC-93B–/– fibroblasts (Supplemental Figure
MDA5-dependent manner in MEFs (31, 42), and that, like hPIV3,
induces normal levels of IFN production in TLR3-deficient human
5B). We further determined basal mRNA levels for IFNB, IFNL1
fibroblasts (10, 13). EMCV also replicated to high levels in cells
(IL29), and downstream ISGs, including CXCL10 and IFI44L, in
with TLR3 pathway deficiencies (TLR3, UNC93B1, NEMO) or IFN
unstimulated fibroblasts. Control cells contained larger amounts
pathway deficiencies (STAT1, STAT2) (Figure 3D). Finally, consisof mRNA for these genes than SV-40 fibroblasts from patients
tent with our previous reports of enhanced HSV-1 replication in
with TLR3, UNC93B, or NEMO deficiency (Figure 4, A–D) whose
TLR3 pathway–deficient fibroblasts (9, 10), we detected higher
TLR3 response signaling was impaired (9, 11, 13). Fibroblasts
levels of HSV-1 viral ICP27 RNA in TLR3 pathway–deficient or
from previously reported patients with IRAK4 or MYD88 defiJ Clin Invest. 2021;131(1):e134529 https://doi.org/10.1172/JCI134529
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Figure 4. Impact of TLR3 signaling deficiencies on basal IFN-related gene expression. mRNA levels of IFNB
(A), IFNL1 (B), CXCL10 (C), and IFI44L (D) (relative to GAPDH) in unstimulated fibroblasts from healthy controls
(C1–C4) and individuals deficient for TLR3-IFN signaling, as quantified by RT-qPCR with normalization against
C1. Representative data from 3 independent experiments are shown. The error bars indicate SDs of triplicate
measurements. (E) Gene expression profile of the ISGs differentially expressed in patients with STAT1 (blue
bar) and TLR3 (orange bar) deficiencies, relative to mean expression levels in controls, as assessed by RNASeq. The heatmap shows the log fold-change in ISG expression, with red indicating upregulation and green
downregulation. P values were obtained for likelihood ratio tests by comparing each patient’s fibroblasts with
control fibroblasts (A–D), and the respective P values are indicated. **P < 0.01, ***P < 0.001.
6

ciencies, in which responses to all
TLRs except TLR3 were impaired,
displayed normal levels of IFNs and
ISGs mRNA (Supplemental Figure
5C). Basal levels of mRNA for IFNB,
IFNL1, CXCL10, and IFI44L were
also lower in SV-40 fibroblasts from
patients with STAT1 and STAT2 deficiency whose IFN response signaling
is impaired than in control cells (Figure 4, A–D) (40, 41). The immortalization of fibroblasts with SV-40 T antigen has been reported to affect IFN
immunity (43). We then analyzed the
transcriptomes of control, TLR3 –/–,
and STAT1–/– primary fibroblasts by
RNA sequencing (RNA-Seq) to rule
out the possibility that the apparently TLR3-IFN signaling–related basal
levels of IFN and ISG were an SV-40
fibroblast–specific phenomenon. We
found that mRNA for 716 fibroblastic
ISGs, but not IFNs, was detectable in
control primary fibroblasts in basal
conditions. mRNA levels were significantly lower in both TLR3 –/– and
STAT1–/– primary fibroblasts than in
control cells for 43 of the 225 differentially expressed ISGs, whereas 13
ISGs were upregulated in these cells
relative to control cells (Figure 4E,
Supplemental Figure 5D, Supplemental Table 1). An analysis, with DAVID
software (44), of the 43 ISGs with low
basal expression levels further confirmed the significant downregulation of type I IFN signaling pathway
genes and antiviral immune genes in
TLR3 –/– and STAT1–/– primary fibroblasts (Supplemental Table 2). Thus,
TLR3 and IFN signaling deficiencies
have a profound impact on basal
IFN-β production and ISG expression
in SV-40–transformed and primary
fibroblasts in the absence of exogenous stimulation, demonstrating the
role of TLR3 in maintaining constitutive antiviral gene expression.
Low basal levels of IFN production underlie the enhanced viral growth
in TLR3-deficient fibroblasts. We
assessed the importance of basal levels of IFN production in control cells,
by neutralizing the IFNs and assessing the impact of this intervention on
VSV replication. We cultured UNC93B–/–, STAT1–/–, and control SV-40
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Figure 5. Constitutive IFN-β production in fibroblasts is TLR3 dependent. Replication of VSV-WT (A) and VSV-M51R (B) in fibroblasts from a healthy
control (C1) or patients with UNC-93B or STAT1 deficiency, cultured in the presence or absence of neutralizing antibodies against IFN-α, -β, and -λ (IFN Nab).
(C) CXCL10 mRNA levels in unstimulated fibroblasts after treatment with IFN NAb for 24 hours. (D) IFN-β and IFN-λ1 (IL-29) mRNA levels in TLR3–/– fibroblasts transfected with WT TLR3, measured by RT-qPCR and normalized against GUS expression. Replication of VSV-WT (E) and VSV-M51R (F) in TLR3–/–
fibroblasts stably transfected with empty vector (+EV) or WT TLR3 (+TLR3). Replication of VSV-WT (G) and VSV-M51R (H) in UNC-93B–/– fibroblasts stably
transfected with empty vector or WT UNC-93B (+UNC-93B). Representative results are shown for 3 (A, B, E–H) or 2 (C–D) independent experiments. The error
bars indicate SDs of biological triplicates (C, D) or the SEM of biological triplicates (A, B, E–H). P values were obtained through log transformation followed by
1-way ANOVA and subsequent Tukey’s multiple comparison tests, and the respective P values are indicated. **P < 0.01, ***P < 0.001, ****P < 0.0001.

fibroblasts in the presence or absence of neutralizing polyclonal
antibodies (NAbs) raised against IFN-α, -β and -λ, for 72 hours. We
measured VSV-WT and VSV-M51R growth kinetics over 24 hours.
Viral titers were similar in UNC-93B–/– and STAT1–/– fibroblasts with

and without NAbs. By contrast, the growth of VSV in control fibroblasts was greater at 8 and 24 hours after infection in the presence
of anti-IFN NAbs than in their absence (Figure 5, A and B), suggesting a substantial contribution of basal IFN production, which
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Figure 6. TLR3-dependent constitutive IFN-β production
restricts VSV growth. (A) TLR3–/– (left panel) and UNC93B–/–
(right panel) fibroblasts were subjected to pretreatment with
conditioned medium from unstimulated cell cultures (as
indicated in parentheses) for 18 hours and infected with VSVM51R for 24 hours. VSV-G mRNA levels were then assessed
by RT-qPCR, with normalization against GAPDH. (B) Similar
to A, except that HSV-1 GFP was used to infect cells and ICP27
mRNA levels were measured by RT-qPCR. (C) TLR3–/– (left
panel) and UNC93B–/– (right panel) fibroblasts were treated
with conditioned medium, as indicated in parentheses, for
24 hours and CXCL10 expression was then quantified by
RT-qPCR. The error bars indicate SDs of biological triplicates
from 3 independent experiments. P values were obtained for
likelihood ratio tests, by comparing each patient’s fibroblasts
treated with conditioned medium from control or patient
fibroblasts, and the respective P values are indicated. **P <
0.01, ***P < 0.001, ****P < 0.0001.

was below the limit of detection for ELISA, in limiting viral growth.
Consistent with this interpretation, basal ISG CXCL10 mRNA
levels were strongly decreased by NAb treatment (Figure 5C). We
then rescued TLR3 signaling in TLR3–/– SV-40 fibroblasts by ectopically expressing WT TLR3 to demonstrate the requirement of
TLR3 signaling for this constitutive antiviral response limiting viral
replication. Basal levels of IFNB and IL29 mRNA were restored to
8

levels similar to those in a healthy control following the
expression of WT TLR3 (Figure 5D). In TLR3–/– cells complemented with WT TLR3, replication rates for VSV-WT
and VSV-M51R were lower than those in nontransfected
TLR3–/– cells or in TLR3–/– cells transfected with an empty
vector (Figure 5, E and F). A similar rescue was observed
in the growth curve of VSV-WT and VSV-M51R in WT
UNC-93B–expressing UNC-93B–/– fibroblasts (Figure 5,
G and H). Collectively, these experiments demonstrate
that a lack of TLR3 signaling results in a deficiency of cellintrinsic, constitutive antiviral IFN responses in fibroblasts, leading to early viral replication that may overwhelm the activity of RIG-I–dependent IFN production,
which is induced later in response to viral replication.
Basal IFN-β production by control cells restricts viral
growth. In human fibroblasts, IFNB was the only interferon gene strongly expressed in basal conditions, and only
IFNB, IFNL1, IFNL2, and IFNL2 displayed a strong induction of expression upon activation of the TLR3 or MAVS
pathway (Supplemental Figure 1). However, these cells
did not express the receptor for type III IFNs (Supplemental Figure 6A). We hypothesized that the basal production
of small amounts of IFN-β by healthy control cells can
rescue the TLR3-deficient cell phenotype. We evaluated
the effects of basal IFN, by stimulating patients’ SV-40
fibroblasts with conditioned medium from healthy control unstimulated cell cultures. This medium effectively decreased the growth of VSV-M51R (Figure 6A)
and HSV-1 (Figure 6B, Supplemental Figure 6B) at 24
hours in TLR3 –/– and UNC-93B–/– cells from patients,
to levels below those in cells treated with medium
from TLR3 –/– and UNC-93B–/– fibroblasts, with virus
titers close to those measured in control cells. Moreover, mRNA levels for ISGs, including CXCL10, MxA, and RIG-I,
were upregulated in the patients’ fibroblasts by stimulation with
conditioned medium from healthy controls, but not with conditioned medium from TLR3–/– and UNC-93B–/– fibroblasts (Figure
6C, Supplemental Figure 6C). Fibroblasts are unable to respond
to IFN-λ, probably because they lack IFNLR expression (Supplemental Figure 6A) (45). However, the pretreatment of TLR3 sig-
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Figure 7. TLR3 ablation decreases ISG expression and increases
vulnerability to viruses in
MEFs. (A) Gene expression
profile of all differentially
expressed ISGs in Tlr3–/– MEFs
relative to mean levels in WT
mice, as assessed by RNASeq. The heatmap shows the
log fold-changes of ISG gene
expression, with red indicating
upregulation and green downregulation. (B) ISG expression
was assessed in unstimulated
WT and Tlr3–/– MEFs, by RT-qPCR with normalization against
RPL19. WT and Tlr3–/– MEFs
were infected with VSV-WT (C)
and VSV-M51R (D) for 24 hours.
Viral RNA levels were then
quantified by RT-qPCR, with
normalization against RPL19.
The error bars indicate SDs of
technical triplicates.

naling–deficient fibroblasts with either IFN-β or IFN-α2b can rescue resistance to viral infection, consistent with the relatively high
levels of IFNAR expression (Supplemental Figure 6A). We found
that IFN-β NAbs abolished both the protection against VSV-M51R
growth and ISG induction conferred by the conditioned culture
medium from control fibroblasts (Supplemental Figure 6, D and
E), demonstrating that IFN-β is the protective cytokine in this context. STAT1–/– fibroblasts failed to upregulate ISGs when treated
with conditioned medium from healthy controls (Supplemental
Figure 6E), suggesting that the IFN signaling pathway is essential
for the maintenance of basal ISG expression by basal IFN levels.
Thus, TLR3-dependent, constitutive IFN-β production governs
intrinsic antiviral immunity in human fibroblasts.
TLR3 also controls constitutive antiviral IFN immunity in mouse
fibroblasts. We investigated whether TLR3-dependent constitutive IFN responses also governed cell-intrinsic constitutive antiviral immunity in MEFs. In mice, spontaneous IFN-α/β production
in vivo in the absence of viral infection primes and enhances the
immune response (46–48). We performed RNA-Seq on WT primary MEFs and Tlr3–/– MEFs to determine whether TLR3 plays
a critical role in controlling cell-intrinsic basal IFN and antiviral
immunity in mouse cells. Basal mRNA levels were significantly

lower in Tlr3–/– MEFs than in Tlr3 WT MEFs for 38 of the 42 ISGs
differentially expressed in WT and Tlr3–/– MEFs, whereas 4 ISGs
were more strongly expressed in these cells than in Tlr3 WT
MEFs (Figure 7A, Supplemental Figure 7A, Supplemental Table
3). Seven of the 38 ISGs downregulated in Tlr3–/– MEFs were also
downregulated in TLR3-deficient human fibroblasts, but different ISGs were upregulated in mouse and human TLR3-deficient
fibroblasts (Supplemental Figure 7B, Supplemental Table 4). As
in human fibroblasts, an analysis of the 38 ISGs downregulated
in Tlr3–/– MEFs with DAVID software (44) confirmed a significant
downregulation of type I IFN signaling pathway genes and antiviral immune genes (Supplemental Table 5). We confirmed these
findings by measuring basal levels of expression for several ISGs
by RT-qPCR. Consistent with the human data, Tlr3–/– MEFs had
lower levels of mRNA for various ISGs, including Ifit1, Ifit2, and
Ifit3 (Figure 7B). Finally, we assessed the viral susceptibility of
MEFs by measuring viral RNA levels after infection with VSV-WT
and -M51R. Tlr3–/– MEFs were more susceptible to both VSV-WT
and -M51R than Tlr3 WT MEFs, as high levels of VSV RNA were
detected in Tlr3–/– MEFs as early as 5 hours after infection (Figure
7, C and D; Supplemental Figure 7, C and D). These data suggest
that TLR3 signaling controls constitutive antiviral IFN immunity
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Figure 8. TLR3 controls basal IFN-β and
antiviral immunity in cortical neurons.
HPSC-derived cortical neurons from 2
control lines (hESC control, iPSC control),
a CRISPR/Cas9-mediated TLR3 knockout
(TLR3-KO) line, and a TLR3–/– patient line
were infected with VSV-WT (A), VSV-M51R
(B), or HSV-1 (C) for the indicated times.
Viral replication was assessed in 50% TCID50
assays. (D) IFN-β levels were measured
in the culture supernatants of hPSC-derived cortical neurons, by Simoa digital
ELISA. (E) Gene expression profile of the
ISGs differentially expressed in patients
with TLR3 (orange bar) and STAT1 (blue
bar) deficiencies, relative to controls, as
assessed by RNA-Seq. (F) Gene expression
profile of the ISGs differentially expressed
in TLR3-KO iPSC-derived cortical neurons,
relative to parental control iPSC-derived cortical neurons. The heatmap shows the log
fold-change in ISG expression, as assessed
from 2 technical duplicates of the RNA-Seq,
with red indicating upregulation and green
downregulation. The error bars indicate the
SEM (A–C) or SDs (D) of biological triplicates
from 3 independent experiments. P values
were obtained with (A–C) or without (D) log
transformation followed by 1-way ANOVA
and subsequent Tukey’s multiple comparison tests, by comparing TLR3–/– or TLR3-KO
cortical neurons with controls, and the
respective P values are indicated. *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001.

in both mouse and human fibroblasts, which use this mechanism
to restrict infection with various viruses.
Impaired basal IFN-β and intrinsic antiviral immunity in
TLR3-deficient iPSC-derived cortical but not TG neurons. We previously showed that TLR3 deficiency impairs cell-autonomous
defense against HSV-1 infection in iPSC-derived cortical neurons
and oligodendrocytes, but not astrocytes, neural stem cells, and
TG neurons (25, 26). As with fibroblasts, prior treatment (but not
treatment at the time of infection) of TLR3 pathway–deficient
iPSC-derived cortical neurons and oligodendrocytes with recom10

binant IFN-α2b or -β, but not IFN-λ, protected them against HSV-1
replication (25, 26). We investigated whether our findings for fibroblasts also applied to cortical and TG neurons. We derived cortical
and TG neurons from one healthy control iPSC line, one healthy
hESC line, an iPSC line from a patient with AR complete TLR3
deficiency (26), and an isogenic TLR3-KO iPSC line that we generated by CRISPR/Cas9-mediated gene editing (Supplemental Figure 8, A and B) (49). As in SV-40 fibroblasts, virus-induced IFNB
and IFNL1 induction occurred late, 16 and 24 hours after HSV-1
infection (Supplemental Figure 8, C and D). When cortical neurons
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were infected with VSV-WT, VSV-M51R, and HSV-1, higher levels
of viral replication were observed as early as 6 hours after infection in TLR3-deficient cells, confirming that TLR3 is essential for
the control of HSV-1 in these cells, and showing that this receptor
is also essential for control of the 2 types of VSV tested (Figure 8,
A–C). By contrast, the replication of the 3 viruses was not higher
in TG neurons lacking TLR3 than in the other cells (Supplemental Figure 8, E–G). TLR3 protein levels were undetectable in both
patient-specific and isogenic TLR3-deficient iPSC-derived cortical
neurons, as shown by Western blotting (Supplemental Figure 8A).
We also assessed basal IFN-β protein secretion by cortical neurons
in the Simoa assay (50). We showed that basal levels of IFN-β production were low in TLR3-deficient cells (Figure 8D). We further
analyzed the transcriptomes of control iPSC-derived cortical neurons, comparing them with those of TLR3-deficient patient and
isogenic TLR3-KO iPSC-derived cortical neurons. Consistent with
our results for fibroblasts, TLR3-deficient cortical neurons had
low levels of ISG mRNAs (Figure 8, E and F; and Supplemental
Figure 9, A and B). The IFN mRNAs themselves were not detected
by RNA-Seq. In total, we detected the expression of 734 ISGs in
control cortical neurons in basal conditions. The mRNA levels
for these genes were significantly lower in both TLR3-deficient
patient and TLR3-KO cortical neurons than in control cells, for 243
of 265 and 283 of 311 differentially expressed ISGs, respectively,
whereas 22 and 28 ISGs were upregulated in these cells relative to
control cells (Supplemental Figure 9, C and D; and Supplemental
Table 6). As many as 196 of the downregulated ISGs and 9 of the
upregulated ISGs were common to TLR3-KO and TLR3-deficient
patient neurons. An analysis with DAVID software (44) of the 196
ISGs with low basal levels of expression confirmed the significant
downregulation of the genes controlled by the IFN-α/β–responsive pathway, and of antiviral genes in both TLR3-KO and TLR3deficient cortical neurons (Supplemental Table 7). Collectively,
these findings strongly suggest that TLR3 also controls constitutive levels of IFN-β, and thus, cell-intrinsic antiviral immunity, in
human hPSC-derived cortical neurons. This process is crucial for
infection control, at least for VSV and HSV-1 in vitro and, by inference, probably HSV-1 in vivo.

Discussion

We describe an unexpected role of TLR3 signaling in antiviral
immunity: as a rheostat controlling constitutive low-level production of IFN-β, which is crucial for limiting viral replication at
early stages in the viral infection of dermal fibroblasts and cortical
neurons. IFN-β was previously thought to be the fibroblastic IFN
because it was discovered in these cells, in which no other type I
IFNs were detectable (51). In most other cells, it is the first IFN
to be induced after viral infection, triggering the amplification
of other IFNs via IRF7 (52). We discovered that the restriction of
VSV growth in human fibroblasts was heavily dependent on the
TLR3-dependent basal IFN-β production of these cells, rather
than their recognition of VSV and the subsequent RIG-I–dependent induction of IFN-β. Basal IFN-β production is impaired in
TLR3–/– and UNC-93B–/– fibroblasts, and these cells are therefore
overwhelmed by VSV-WT and even M51R replication within as
little as 6 hours after infection, before the RIG-I–dependent induction of IFN-β production in response to viral infection. This situa-

tion contrasts with that in healthy control fibroblasts, in which VSV
replication and cell death are limited by basal IFN-β levels, which
are higher not only than those in UNC-93B–/– and TLR3–/– cells, but
also than those in NEMO –/–, STAT1–/–, and STAT2–/– cells. In human
fibroblasts lacking TLR3 signaling (e.g., UNC-93B–/–, TLR3–/–,
NEMO–/–), the impairment of constitutive low-level TLR3-dependent IFN-β production may reduce the responsiveness and intrinsic defenses of uninfected cells against viral infection, by reducing
the basal level of expression of specific ISGs. In cells lacking IFN
signaling responses (e.g., STAT1–/–, STAT2–/–), impaired responses
to IFN-β result in lower levels of basal expression for ISGs, including TLR3 and STAT1. As a more general consequence, fibroblasts
lacking TLR3 and IFN signaling are highly susceptible to infection
with the 3 RNA viruses (VSV, hPIV3, EMCV) and the DNA virus
(HSV-1) tested, regardless of the levels of IFN-β induction by these
viruses. Similarly, TLR3-deficient iPSC-derived cortical neurons
are highly susceptible to infection with VSV and HSV-1. Collectively, our data indicate that inborn errors of the TLR3 pathway
impair basal and protective IFN-β antiviral immunity in human
fibroblasts and cortical neurons.
We have shown that this TLR3 rheostat also operates in mouse
fibroblasts. Previous studies have shown that Tlr3 –/– mice are no
more susceptible than their WT littermates to VSV, lymphocytic
choriomeningitis virus, or reovirus (53), and that they are even
more resistant to Punta Toro virus (54), influenza virus (55), and
vaccinia virus (56). Mouse fibroblasts may not have been infected
in the course of such experiments, or their contribution to host
defense may be compensated by other cells. However, mouse
TLR3 is required for antiviral immunity to mouse cytomegalovirus
(57), respiratory syncytial virus (58), coxsackievirus group B serotype 3 (CVB3) (59), and coxsackievirus B4 (CVB4) viruses (60).
The contribution of fibroblasts in these models is unknown. Other
cell types in mice may also control basal IFN-β immunity through
TLR3. Interestingly, the DNA sensor cGAS controls basal levels
of IFNs and ISGs in mouse bone marrow–derived macrophages
(61). It is therefore possible that TLR3 and cGAS control basal
ISG levels in different cell types. In certain cell types, both may
be required for basal antiviral immunity. Mouse cGAS is essential
for defense against various infections, including HSV-1 infection
(30). The genetic ablation of cGAS revealed that this protein was
required for antiviral responses to both DNA viruses and RNA
viruses in vivo (61). Future studies with single and double knockouts of TLR3 and cGAS in mice and humans may delineate the
respective contributions of TLR3 and cGAS, as viral sensors versus
rheostats of IFN immunity in host defense. Virus-induced IFN-α/β
and IFN-λ production could be protective against viral infection in
vivo, probably following the earliest stage of viral infection. The
study of MDA5 and RIG-I in this context is also warranted by the
identification of patients with MDA5 deficiency displaying selective vulnerable to respiratory viruses (62, 63). The identification of
patients with cGAS, STING, or RIG-I deficiency could provide new
insight into this aspect.
The natural TLR3 stimuli controlling basal IFN-β production in fibroblasts and cortical neurons remain unknown. In the
absence of exogenous stimulation, endogenous ligands such as
mRNAs or debris from necrotic cells can trigger TLR3 signaling in
human dendritic cells (64) and murine macrophages (65), respec-
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tively. Self-noncoding RNAs generated during cell damage and
the microtubule regulator stathmin have been identified as endogenous agonists of TLR3 in human keratinocytes and in human
astrocytes and microglia cells, respectively (66, 67). One or more
of these known cell-endogenous agonists may activate TLR3 in
fibroblasts, cortical neurons, and other cells, thereby contributing
to basal IFN and ISG production. However, it remains possible
that TLR3 can sustain basal activation in the absence of stimulation with any ligand. In any event, our study clearly demonstrates
that TLR3 is essential for the maintenance of constitutive IFN-β
immunity in human fibroblasts and cortical neurons, and this
observation also applies to mouse fibroblasts. It may also operate
in other CNS-resident cells, such as oligodendrocytes, in which
the control of HSV-1 is also dependent on TLR3, contrasting with
the situation in astrocytes, neural stem cells, and TG neurons (25,
26). Constitutive TLR3 activity in the brain may also be important
in the prevention of other neurological conditions via mechanisms
that may or may not be related to IFN-mediated immunity (68,
69). While we cannot yet discern the respective roles of constitutive and virus-induced cell-intrinsic IFN immunity in the course
of natural infection with HSV-1 in TLR3-deficient individuals,
our findings provide a plausible molecular and cellular basis for
HSE in patients with inborn errors of TLR3 immunity. They also
suggest that IFN-α/β, rather than IFN-λ, are critical for protective
immunity to HSV-1 in the CNS.
Our findings also suggest that TLR3-dependent cell-intrinsic
constitutive IFN immunity may be a critical first line of defense
against HSV-1 and perhaps other viruses in certain tissues, and its
disruption may result in tissue-specific severe viral infections in
various organs. Patients with TLR3 deficiency may also be more
susceptible to diseases other than HSE. This was confirmed by our
recent identification of 3 unrelated patients with TLR3 mutations
and severe influenza pneumonia (70), a finding that is consistent
with TLR3 being a major IFN-β– and IFN-λ–inducing receptor in
human and mouse pulmonary epithelium cells (PECs), in which
large amounts of IFN-λ may be produced with potent antiviral
activity (70, 71). Furthermore, a deleterious TLR3 mutation has also
been found in a patient with varicella zoster virus ophthalmic neuritis (72). Overall, our findings indicate that TLR3 controls baseline
tone of IFN-β and IFN-λ in dermal fibroblasts and of IFN-β in cortical neurons (both cell types respond to IFN-β but not IFN-λ). They
also suggest that TLR3 may control baseline levels of IFN-β and/
or IFN-λ in PECs (which respond to both IFN-β and IFN-λ). The
genetic dissection of various viral diseases, including coronavirus
disease 2019 (COVID-19) (73–75), may help to delineate the roles
of human TLR3 and other IFN-inducing sensors in host defense.
It also seems likely that deficiencies of other type I IFN responsiveness circuit genes (e.g., IRF7, IRF9, STAT1, STAT2, IFNAR1,
IFNAR2) render patients prone to a broad spectrum of viral diseases, other than the previously reported phenotypes including severe
influenza pneumonia (IRF7, IRF9), HSE (IFNAR1, STAT1), and
severe adverse reactions to live attenuated viral vaccines (IRF9,
STAT1, STAT2, IFNAR1, IFNAR2) (12, 17, 40, 76–79), partly due to
the low basal levels of IFN-β, IFN-λ, and ISG in tissue-specific cells.
Our findings highlight the importance of host cell–intrinsic and
constitutive, as opposed to pathogen-induced, IFN and ISG immunity in antiviral defenses, particularly during early stages of viral
12

infection (80–82). Our findings also suggest that TLR3 may govern
the first line of broad antiviral responses in some cell types, such
as fibroblasts, cortical neurons, and perhaps PECs, or even more
broadly in certain tissues or organs, such as the CNS and lungs in
particular, as opposed to governing immunity to specific viruses,
such as HSV-1, in various cells, tissues, and organs.

Methods

Cells and viruses. Primary fibroblasts were isolated from skin biopsy
specimens from patients with AR UNC-93B, AR STAT1, XR NEMO,
and AR TLR3 deficiencies and healthy controls, as previously
described (9, 11, 13, 41). The fibroblasts were immortalized by transfection with the SV-40 large T antigen and maintained in DMEM supplemented with 10% FBS.
Cells stably expressing shRNAs against RIG-I and MAVS were
generated by transduction with shRNA-expressing retroviral particles
(Santa Cruz Biotechnology). Stably transfected cell lines were generated by transfecting TLR3 –/– or UNC-93B–/– fibroblasts with TLR3 or
UNC-93B WT or empty vector, with Lipofectamine 2000 (Invitrogen). Transfectants were selected in DMEM containing 5 μg/mL blasticidin (Invitrogen).
VSV, Indiana strain, WT, and M51R mutant (harboring a substitution of an arginine residue in place of the methionine in position 51
of the matrix (M) protein) were provided by Pierre Lebon and have
been described elsewhere (10, 39, 83–85). MEFs were generated from
14-day-old WT and Tlr3−/− embryos (86), and maintained in DMEM
supplemented with 10% FBS.
Cell culture of iPSCs and hESCs (together referred to as hPSCs), and
neuronal induction and differentiation. Control MRC5 and TLR3 –/–
patient-specific iPSC lines were reprogrammed with a nonintegrating
Sendai viral vector, as previously described (26). All hPSC lines were
used at passage 20–50, and were maintained on vitronectin with
Essential 8 medium (Fisher Scientific), with twice-weekly passaging
with EDTA (87). The HPSC lines used here were as follows: TLR3–/–
patient-specific iPSCs, control iPSCs MRC5, isogenic MRC5 TLR3 KO
iPSCs, and a control hESC line H9 (WA-09) (26). All cell lines were
karyotyped to ensure genomic integrity and weekly tests for myco
plasma were performed. TG neuron and cortical neuron differentiation was performed as previously described (26).
Cell stimulation. SV-40 fibroblasts were plated at a density of 105
cells per well in a 24-well plate and were incubated overnight. Polyinosinic-polycytidylic acid (poly(I:C); Amersham) was added to the
culture medium at a concentration of 25 μg/mL, transfected with the
RIG-I agonist, 7sk-as at a concentration of 0.45 ng, or with 25 μg of
poly(I:C), with Lipofectamine 2000 (Invitrogen), or infection with
VSV at the indicated MOIs, and the culture medium was harvested
after 24 hours of stimulation. Cytokine concentrations in culture
medium were determined by ELISA.
Measurement of cytokine production. IFN-β production was
assessed in an enzyme-linked immunosorbent assay (ELISA; TFB
Fujirebio). For IFN-λ determinations, culture supernatants were
incubated for 2 hours in plates coated with 1 μg/mL monoclonal
anti-human IL29 antibody (R&D Systems). A biotinylated monoclonal secondary antibody directed against human IL-29 (R&D Systems) and streptavidin peroxidase were added, together with TMB
(3,3′,5,5′-tetramethylbenzidine). The signal at 450 nm was then read
with a plate fluorescence reader.

J Clin Invest. 2021;131(1):e134529 https://doi.org/10.1172/JCI134529

RESEARCH ARTICLE

The Journal of Clinical Investigation  
Immunoblotting. Cells were lysed in NP40 lysis buffer (280 mM
NaCl, 50 mM Tris pH 8, 0.2 mM EDTA, 2 mM EGTA, 10% glycerol, 0.5% NP40) supplemented with 1 mM DTT, 5 mM Na3VO4, and
Complete protease inhibitor cocktail (Roche). The protein lysate
was subjected to SDS-PAGE and the bands obtained were transferred to a PVDF membrane, which was probed with unconjugated
rabbit anti–RIG-I (Cell Signaling, catalog 3743), goat anti-MAVS
(Santa Cruz Biotechnology, catalog sc-365333), TLR3 (R&D Systems, catalog 1487) and HRP-conjugated secondary antibodies. A
β-tubulin antibody (MilliporeSigma, catalog T4026) and a GAPDH
(Santa Cruz Biotechnology, catalog sc-365062) antibody were used
as loading controls.
For the detection of dsRNA in VSV-infected cells, SV-40 fibroblasts were infected as described above, with VSV at a MOI of 10 for
8 hours. RNA was isolated with TRIzol reagent (Invitrogen), according to the manufacturer’s protocol. We subjected 30 μg total RNA to
electrophoresis in a 1.5% agarose/TBE gel, and the bands were then
transferred to a nylon membrane (Hybond N+, GE Healthcare). The
RNA was fixed by ultraviolet irradiation, probed with the anti–dsRNA
antibody K1, and the blot was developed for enhanced chemiluminescence (Pico ECL, Pierce).
Viral assays. SV-40–transformed fibroblasts were plated at a
density of 105 cells per well in 24-well plates. For one-step growth
curves, the cells were incubated with VSV-WT and -M51R, hPIV3,
EMCV, or HSV-1 at the indicated MOI for 30 minutes or 1 hour,
washed twice in PBS, and then transferred to fresh DMEM. Virus
samples were collected at the indicated times and the viral titer was
determined by 50% tissue culture infective dose (TCID50) assays
on Vero E6 cells (for VSV and hPIV3), according to the Reed and
Muench calculation (13), or by qPCR methods for EMCV (88), determinations of ICP27 mRNA levels for HSV-1, and determinations of
VSV-G mRNA levels for VSV.
For coinfection experiments, cells were infected with VSV-WT at
a MOI of 3 and with VSV-M51R at a MOI of 1 in DMEM supplemented with 10% FBS for 24 hours. VSV-WT and -M51R were inactivated
by exposure to ultraviolet light for 10 minutes at a distance of 15 cm.
Cytokine production was measured in the culture medium by ELISA.
For IFN neutralization experiments, cells were cultured in the
presence of neutralizing polyclonal antibodies against IFN-α and -β
(PBL), replaced daily for 3 days. They were then infected with VSV-WT
or -M51R at a MOI of 3, as described above. Samples were harvested at
the times indicated and titered on Vero cells.
Cytotoxicity assays. Cells were plated at a density of 2 × 104 cells
per well in 96-well plates, in DMEM with or without IFNα2b (105
IU/mL, Schering-Plough) treatment for 18 hours. The medium was
replaced with medium containing VSV at the indicated MOIs. Mortality was assessed 24 hours after infection, with the LDH Cytoxicity
Detection KitPLUS (Roche). The death of cells is expressed relative to
that of uninfected cells. For hPIV3 infection, fibroblasts were plated
as above and infected at the indicated MOIs. Viability was assessed
in a resazurin-based viability assay (MilliporeSigma). The viability of
infected cells is expressed relative to that of uninfected cells.
Determination of mRNA levels by RT-qPCR. Total RNA was extracted
from cells with TRIzol (Invitrogen) or the RNeasy kit (QIAGEN). Samples were treated with DNase at 37°C for 1 hour and cleaned by passage
through an RNeasy column (QIAGEN). Reverse transcriptase-PCR was
performed with random hexamers (Applied Biosystems). RT-qPCR

was performed with Applied Biosystems TaqMan assays, using the
β-glucuronidase (GUS) housekeeping gene for normalization, or in
SYBR Green assays with the GAPDH (human) or RPL19 (mouse)
housekeeping gene for normalization. Results are expressed according
to the ΔΔCt method, as described by the manufacturer.
RNA sequencing and analysis. Total RNA was extracted from
human primary fibroblasts, C57BL/6 mouse primary fibroblasts,
or hPSC-derived cortical neurons. RNA samples were treated with
DNase (Ambion) to remove residual genomic DNA. RNA-Seq libraries
were prepared with the Illumina RiboZero TruSeq Stranded Total RNA
Library Prep Kit (Illumina) and sequenced on the Illumina NextSeq
platform in the 150 nt with paired-end configuration. We sequenced
3 (human samples) or 2 (mouse samples) technical replicates for each
sample. The raw sequencing data is available under National Center
for Biotechnology Information Sequence Read Archive (NCBI-SRA)
accession number SRP288648.
The RNA-Seq FASTQ raw data were inspected with multiQC
v1.6 to ensure that they were of high quality (89). The sequencing
reads of human and mouse samples were mapped onto the UCSC
human reference genome GRCh37/hg19 and the UCSC mouse reference genome GRCm38/mm10, respectively (90), with STAR aligner
v2.6 (91). The quality of each mapped alignment in BAM files was
evaluated with RSeQC (92). Reads were quantified to determine the
number of gene-level read counts forming the read alignment, with
featureCounts v1.6.0 and GENCODE GRCh37.p13 human gene annotation V19 and GENCODE GRCm38.p6 mouse gene annotation M19,
respectively (93, 94). The gene-level read counts were normalized and
log2-transformed by DESeq2 to obtain the gene expression value for all
genes and all samples (95).
We extracted expression data for 905 ISGs based on our previous
IFN-stimulated microarray data analysis (13). Differential ISG expression was analyzed by applying TMM normalization and gene-wise
generalized linear model regression in edgeR (96). The ISGs displaying
significant differential expression were selected on the basis of a FDR
< 0.05. We used ComplexHeatmap (97) to plot a heatmap of the foldchange in gene expression. Gene set enrichment analysis was performed
with Ingenuity Pathway Analysis (IPA) (98) and DAVID (44) software.
Conditioned medium experiments. Conditioned culture medium was
harvested from healthy control, TLR3–/–, or UNC-93B–/– unstimulated cell
cultures after 2 days of culture. Cell debris was removed by centrifugation. Healthy control, TLR3–/–, UNC-93B–/–, or STAT1–/– fibroblasts were
then cultured in fresh DMEM. The conditioned culture supplemented
with 100 U neutralizing antibodies against IFN-β or -α or normal sheep
serum (isotype control) was added to the culture medium of the cells,
and was maintained in the medium for 18 hours. RNA was isolated for
RT-qPCR, and VSV growth was measured at the time points indicated.
Gene editing. Gene-editing experiments were performed as previously described (99). Briefly, guide RNA (gRNA) sequences were generated with the CRISPR design tool (http://crispr.mit.edu/). GTCATCGAATCAAATTAAAG was selected as the guide sequence. Forward
and reverse oligonucleotides for each gRNA were then inserted into
the MLM3636 vector (Addgene, 43860). We electroporated 2 million
hPSCs with 20 μg of Cas9-GFP plasmid and 5 μg gRNA plasmid mixed
in electroporation buffer (BTX, catalog 45-0805). Green cells were
sorted by FACS 48 hours after electroporation. About 50,000 cells
with a moderate GFP fluorescence intensity were cultured, plated at
clonal density in 96-well plates, and amplified. Genomic DNA was
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then extracted from each clone and Sanger sequencing for TLR3 was
performed. Forward: 5′-CAACACTCCACCTCACTATC-3′; reverse:
5′-CATTGAAGAGAAATGTTCCCAGAC-3′. The TLR3-KO line used
in this study carries a homozygous insertion that leads to a frameshift
at amino acid position 210 and a premature stop codon 17 amino acids
later (c. 628A>AA; p. K210fs17*).
Simoa assay. IFN-β protein levels were quantified in a digital ELISA (Simoa, Quanterix) developed with the Quanterix Homebrew kit,
as previously described (50).
Statistics. Data are expressed as the mean of at least 3 biological replicates ± SD unless otherwise indicated, or are representative
of 3 independent experiments. For most data, linear mixed models
were used for log-transformed relative values, to account for repeated measurements. The difference between cases and controls was
assessed with a likelihood ratio test. Analysis was performed with the
nlme package of R software. Where indicated, 1-way ANOVA tests or
log-transformations followed by 1-way ANOVA tests were used for statistical analysis. Data were analyzed in PRISM7. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001.
Study approval. All experiments were conducted in accordance
with local regulations and with the approval of the institutional review
boards of The Rockefeller University and Institut National de la Santé
et de la Recherche Médicale (INSERM).
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